Study of CD19 CAR T-like cells for hard-to-treat B cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests lab-made immune cells (called 4SCAR19) that are designed to find and attack CD19-positive B-cell cancers that have come back or did not respond to treatment. You may be considered if you meet age, blood test, infection, pregnancy, and general health requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be older than 6 months
- Your cancer must be a B-cell type that shows CD19 on the surface
- Be well enough overall (KPS score above 80) and expected to live more than 3 months
- Have blood counts high enough (hemoglobin above 80 g/L)
- Have no major health problems that make cell collection and processing hard
- Not have uncontrolled infections or certain viral infections (including HIV, active hepatitis B, or active hepatitis C)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lab-made immune treatment (CAR-T cells) designed to attack cancer cells that carry CD19 or CD22. It may help people whose B-cell cancers have those markers, provided they meet safety and health requirements.
This trial tests a new type of immune cell therapy (4SCAR19U T cells) designed to attack B-cell cancers. It may be an option if your cancer has the CD19 protein and you haven't had a prior CAR-T treatment that failed.
This early-phase trial tests a customized immune cell therapy (CAR-T) that targets cancer cells with CD19 or CD70 markers on their surface. It may help your body fight the cancer by directing new immune cells to recognize and attack those cells.
This trial tests a new type of CAR-T cell therapy that targets multiple markers on B-cell lymphoma cells. It is for patients whose lymphoma has certain surface markers and who are in reasonably good health.
This trial tests a lab-made immune therapy called CAR-T that targets specific markers on B-cell leukemia/lymphoma cells. It may help people whose cancer has returned or did not respond after earlier CD19 CAR-T, by attacking the cancer cells using added targeting.
This trial studies a type of immune treatment (CAR-T cells) designed to calm overactive immune disease. It may help by aiming the therapy at immune cells involved in B-cell activity, but it has strict health and safety requirements.
Hear when a new B Cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.